PE7898A1 - Peptidos compuestos que se ligan al receptor de trombopoietina - Google Patents

Peptidos compuestos que se ligan al receptor de trombopoietina

Info

Publication number
PE7898A1
PE7898A1 PE1996000437A PE00043796A PE7898A1 PE 7898 A1 PE7898 A1 PE 7898A1 PE 1996000437 A PE1996000437 A PE 1996000437A PE 00043796 A PE00043796 A PE 00043796A PE 7898 A1 PE7898 A1 PE 7898A1
Authority
PE
Peru
Prior art keywords
thrombopoietine
receptor
rent
trp
link
Prior art date
Application number
PE1996000437A
Other languages
English (en)
Inventor
William J Dower
Steven E Cwirla
Sherril S Johnson
David J Duffin
Christopher R Wagstrom
Peter J Schatz
Larry C Mattheakis
Nicholas C Wrighton
Ronald W Barrett
Christian M Gates
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE7898A1 publication Critical patent/PE7898A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

CARACTERIZADOS POR UNA SECUENCIA CICLIZADA O DIMERIZADA DE AMINOACIDOS, QUE COMPRENDE: CX2X3X4X5X6X7 O X9X8GX1X2X3X4X5WX7, EN DONDE PREFERENTEMENTE: X1 ES P; X2 ES T; X3 ES L; X4 Y X6 SON R; X5 ES E o Q; X7 ES I o L; X8 ES D, E o K; X9 ES A o I; EN DONDE: P ES Pro, T ES Thr, L ES Leu, R ES Arg, G ES GLY, E ES Glu, Q ES Gln, I ES Yle, D ES Asp, K ES Lys, A ES Ala, C ES Cys, W ES Trp, S ES Ser, F ES Phe, W ES Trp; ESTA SECUENCIA PREFERENTEMENTE COMPRENDE: CADGPTLREWISFC O IEGPTLRQWLAARA, EN DONDE: A) OPCIONALMENTE, LOS ENLACES PEPTIDICOS HAN SIDO REEMPLAZADOS POR GRUPOS: -CH2-O-CONR-, -CH2-SO2-NR-, -CH2-NR-, -CO-NR6, -NHCO-NH- O UN ENLACE FOSFONATO; B) N-TERMINAL ES -NRR1, -NR-COR, -NR-COOR, -NR-SO2-R O UN GRUPO SUCCINAMIDA, BENCILOXICARBONILO-NH- OPCIONALMENTE SUSTITUIDO POR 1; 2 o 3 ALQUILO INFERIOR, ALCOXI INFERIOR, Cl o Br; C) C-TERMINAL ES -COR2, EN DONDE R2 ES OH, ALCOXI INFERIOR O NR3R4, EN DONDE: R3 Y R4 SON H, ALQUILO INFERIOR O NR3R4 FORMAN UN PEPTIDO CICLICO; ADEMAS R Y R1 SON H O ALQUILO INFERIOR;Y R6 ES ALQUILO INFERIOR. ESTOS PEPTIDOS PRESENTAN: 1) UN PESO MOLECULAR MENOR A 8 000 DALTONS; 2) UNA AFINIDAD DE ENLACE AL RECEPTOR DE TROMBOPOIETINA, EN IC50 DE NO MAS DE 100�m, SIENDO USADOS EN CASOS DE TROMBOCITOPENIA RESULTANTE DE QUIMIOTERAPIA, DE TERAPIA DE RADIACION O DE TRANSFUSIONES DE MEDULA OSEA
PE1996000437A 1995-06-07 1996-06-07 Peptidos compuestos que se ligan al receptor de trombopoietina PE7898A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48530195A 1995-06-07 1995-06-07
US47812895A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
PE7898A1 true PE7898A1 (es) 1998-03-05

Family

ID=27045796

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000437A PE7898A1 (es) 1995-06-07 1996-06-07 Peptidos compuestos que se ligan al receptor de trombopoietina

Country Status (27)

Country Link
US (2) US6083913A (es)
EP (4) EP2338897A1 (es)
JP (1) JP3059218B2 (es)
KR (1) KR100436680B1 (es)
CN (2) CN1966520B (es)
AR (1) AR003431A1 (es)
AT (1) ATE390439T1 (es)
BR (1) BR9608587A (es)
CA (2) CA2636432C (es)
CZ (1) CZ291749B6 (es)
DE (1) DE69637473T2 (es)
DK (1) DK0885242T3 (es)
EA (1) EA001220B1 (es)
ES (1) ES2303338T3 (es)
HK (1) HK1015380A1 (es)
HU (1) HU227678B1 (es)
IL (1) IL122102A (es)
MX (1) MX9709315A (es)
NO (2) NO317737B1 (es)
NZ (1) NZ310778A (es)
PE (1) PE7898A1 (es)
PL (1) PL188795B1 (es)
PT (1) PT885242E (es)
TR (1) TR199701526T1 (es)
TW (1) TW518341B (es)
WO (1) WO1996040750A1 (es)
ZA (1) ZA964814B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
EP2338897A1 (en) * 1995-06-07 2011-06-29 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
US6172210B1 (en) * 1996-04-02 2001-01-09 Blood Center Research Foundation DNA encoding phospholipid scramblase
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6930084B1 (en) 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
US6593456B1 (en) 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
CA2328252A1 (en) * 1998-04-14 1999-10-21 Katherine Louisa Widdowson Receptor ligands
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
TWI250988B (en) * 1998-10-23 2006-03-11 Kirin Amgen Inc Thrombopoietic compounds
ATE284415T1 (de) 1999-01-06 2004-12-15 Genentech Inc Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
US6911314B2 (en) 1999-05-14 2005-06-28 The Regents Of The University Of California Screening for drugs that affect TNF receptor releasing enzyme
JP2003509478A (ja) 1999-09-21 2003-03-11 エモリー・ユニバーシティ 血小板関連障害を処置する方法および組成物
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
DK1282437T3 (da) 2000-05-16 2008-06-30 Genentech Inc Behandling af brusklidelser
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP3966816B2 (ja) 2000-05-30 2007-08-29 中外製薬株式会社 トロンボポエチン様活性を有する化合物
ATE320450T1 (de) 2000-12-05 2006-04-15 Alexion Pharma Inc Rationell entworfene antikörper
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US7169931B2 (en) 2001-01-26 2007-01-30 Shionogi & Co., Ltd. Cyclic compounds exhibiting thrombopoietin receptor agonism
AU2002307062A1 (en) * 2001-04-02 2002-10-15 Purdue Pharma L.P. Thrombopoietin (tpo) synthebody for stimulation of platelet production
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
AU2002363522A1 (en) * 2001-11-06 2003-05-19 Ho Chris Meichung Wang System and method for improved computer drug design
CN1319967C (zh) * 2002-01-18 2007-06-06 安斯泰来制药有限公司 2－酰基氨基噻唑衍生物或其盐
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
AR040083A1 (es) 2002-05-22 2005-03-16 Smithkline Beecham Corp Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
CA2495184A1 (en) 2002-08-14 2004-02-26 Nissan Chemical Industries, Ltd. Thrombopoietin receptor activators and process for their production
JP2005539082A (ja) 2002-09-18 2005-12-22 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 血小板および造血幹細胞の産生の増大方法
FI20021762A0 (fi) * 2002-10-03 2002-10-03 Karyon Oy Ab Ltd Uusia terapeuttisia aineita ja valmisteita
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
US7736909B2 (en) * 2003-01-09 2010-06-15 Board Of Regents, The University Of Texas System Methods and compositions comprising capture agents
NZ563042A (en) * 2003-05-12 2008-09-26 Affymax Inc Novel spacer moiety for poly(ethylene glycol)-modified peptide-based compounds
MXPA05012313A (es) * 2003-05-12 2006-04-18 Affymax Inc Peptidos que se unen al receptor de eritropoyetina.
DE602004028725D1 (de) * 2003-05-12 2010-09-30 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
KR101163683B1 (ko) 2003-05-12 2012-07-10 아피맥스, 인크. 에리스로포이에틴 수용체에 결합하는 신규의 펩티드
WO2004108078A2 (en) * 2003-06-02 2004-12-16 Alexion Pharmaceuticals Inc. Rationally designed antibodies
US7601746B2 (en) 2003-08-12 2009-10-13 Shionogi & Co., Ltd. Compounds exhibiting thrombopoietin receptor agonism
UA82710C2 (uk) * 2003-08-28 2008-05-12 Орто-Макнейл Фармацевтикал, Инк. Пептид, що зв'язується з тромбопоетиновим рецептором (варіанти), та спосіб лікування тромбоциторенії (варіанти)
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
CN100432102C (zh) * 2004-09-30 2008-11-12 百瑞全球有限公司 血小板增进蛋白及其应用
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
EP1814910A4 (en) * 2004-11-11 2009-04-29 Affymax Inc NEW AT ERYTHROPOIETIN RECEPTOR BINDING PEPTIDES
EP1819692A1 (en) 2004-12-08 2007-08-22 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
CA2590204C (en) 2004-12-14 2012-12-04 Nissan Chemical Industries, Ltd. Amide compounds and thrombopoietin receptor activators
JP5517450B2 (ja) * 2005-03-10 2014-06-11 バイオンテック アーゲー 二量体または多量体のマイクロタンパク質
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EA200800109A1 (ru) * 2005-06-23 2008-06-30 Аплаген Гмбх Суправалентные соединения
JP5071375B2 (ja) 2005-07-15 2012-11-14 日産化学工業株式会社 チオフェン化合物及びトロンボポエチンレセプター活性化剤
TWI330184B (en) 2005-07-20 2010-09-11 Nissan Chemical Ind Ltd Pyrazole compounds and thrombopoietin receptor activators
JP5205967B2 (ja) 2005-11-07 2013-06-05 日産化学工業株式会社 ヒドラジド化合物及びトロンボポエチンレセプター活性化剤
AU2006313491B2 (en) * 2005-11-08 2011-01-06 Astellas Pharma Inc. Compositions and methods for treating thrombocytopenia
US7879318B2 (en) * 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
WO2007142308A1 (ja) 2006-06-07 2007-12-13 Nissan Chemical Industries, Ltd. 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
EP2452674B1 (en) * 2006-08-08 2014-03-26 Akarx, Inc. Compositions and methods for increasing blood platelet levels in humans
WO2008095004A2 (en) * 2007-01-31 2008-08-07 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
US20090054332A1 (en) * 2007-06-21 2009-02-26 Conjuchem Biotechnologies, Inc. Thombopoietin peptide conjugates
CA2694567C (en) 2007-07-31 2013-04-23 Shionogi & Co., Ltd. Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity and intermediate thereof
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
US8278057B2 (en) * 2007-09-14 2012-10-02 Nestec S.A. Addressable antibody arrays and methods of use
US8637455B2 (en) * 2007-10-22 2014-01-28 Affinergy, Llc Compositions and methods for delivery of glycopeptide antibiotics to medical device surfaces
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
US9493551B2 (en) 2009-02-24 2016-11-15 Alexion Pharmaceuticals, Inc. Antibodies containing therapeutic TPO/EPO mimetic peptides
DK3127427T3 (da) 2009-05-29 2020-04-06 Novartis Ag Fremgangsmåder til administration af trombopoietinagonistforbindelser
AU2010253797B2 (en) * 2009-05-29 2015-03-12 Opko Health, Inc. Peptoid ligands for isolation and treatment of autoimmune T-cells
WO2010141421A1 (en) * 2009-06-02 2010-12-09 The Board Of Regents Of The University Of Texas System Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
TW201124726A (en) * 2009-10-16 2011-07-16 Univ Texas Compositions and methods for producing coded peptoid libraries
JP5704073B2 (ja) 2009-10-23 2015-04-22 日産化学工業株式会社 縮環へテロ環化合物及びトロンボポエチンレセプター活性化剤
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
CN104045715B (zh) * 2013-03-15 2018-05-01 兰州大学 二聚体化融合蛋白的制备及应用
BR112017003718B1 (pt) * 2014-09-11 2023-04-11 Bristol-Myers Squibb Company Inibidores macrocíclicos das interações de proteína/proteína de pd- 1/pd-l1 e cd80(b7-1)/pd-l1
EP3658191A1 (en) * 2017-07-26 2020-06-03 Janssen Pharmaceutica NV Methods of protecting vascular integrity induced by targeted radiation therapy
AU2020396647A1 (en) 2019-12-06 2022-07-07 Ajinomoto Co., Inc. Method for producing peptide having physiological activity, and peptide comprising short linker
TW202300178A (zh) 2021-03-18 2023-01-01 美商西根公司 內化的生物活性化合物偶聯物選擇性釋放藥物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3645090A (en) 1969-06-19 1972-02-29 Citizen Watch Co Ltd Day-date quick-adjuster for calender timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4612132A (en) 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5571508A (en) 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
EP0604552B1 (en) 1991-09-18 1997-02-12 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5359115A (en) 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
DE69332222T3 (de) 1992-06-11 2007-05-10 Alkermes Controlled Therapeutics, Inc., Cambridge Enythropoietin enthaltendes arzneimittelabgabesystem
US5420328A (en) 1992-09-11 1995-05-30 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
EP0673387B1 (en) * 1992-12-11 1999-09-22 University Of Florida Materials and methods for control of pests
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
CA2170357A1 (en) 1993-08-25 1995-03-02 David Digiusto Method for producing a highly enriched population of hematopoietic stem cells
WO1995011992A1 (en) 1993-10-27 1995-05-04 The Regents Of The University Of California Antiviral compounds
WO1995011922A1 (en) 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
CN1148408A (zh) 1994-02-14 1997-04-23 津莫吉尼蒂克斯公司 血细胞生成蛋白及其制造材料和方法
AU1843595A (en) 1994-02-14 1995-08-29 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
SG79882A1 (en) 1994-02-14 2001-04-17 Kirin Brewery Protein having tpo activity
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
BR9506017A (pt) 1994-03-31 1997-10-14 Amagen Inc Polipeptide poninculeotídeo isolado sequência de Dna e Cdna vetor de Dna célula hospedeira anticorpo composição farmacêutica derivado de Mgdf produto polípeptídeo Mgdf com grupos peg e preparação do mesmo e processo para produzir um polipeptídeo Mgdf humano e uma condição trombocitopênica para aumentar o número de megacarióticos maduroas e de plaquetas em um paciente necessitado dos mesmos e para fixar um polímero solúvel em água a um polipeptídeo Mgdf uma molècula de polietileno glicol a um polipeptideo Mgdf e poipeptideo glicol solúvel em água a um polipeptideo mgdf
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
AU4163196A (en) * 1994-11-30 1996-06-19 Zymogenetics Inc. Low molecular weight thrombopoietin
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
EP2338897A1 (en) * 1995-06-07 2011-06-29 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US8157793B2 (en) 2006-10-25 2012-04-17 Terumo Kabushiki Kaisha Manipulator for medical use
JP2023049441A (ja) 2021-09-29 2023-04-10 トヨタ紡織株式会社 乗物用シート

Also Published As

Publication number Publication date
IL122102A (en) 2002-07-25
DE69637473T2 (de) 2009-05-07
WO1996040750A1 (en) 1996-12-19
CA2636432C (en) 2012-01-03
KR19990022576A (ko) 1999-03-25
PT885242E (pt) 2008-06-18
NO317737B1 (no) 2004-12-13
CN1192749A (zh) 1998-09-09
EP0885242A1 (en) 1998-12-23
NO975705D0 (no) 1997-12-05
EP1961760A3 (en) 2008-09-03
CZ291749B6 (cs) 2003-05-14
CN1966520B (zh) 2012-07-11
NO331550B1 (no) 2012-01-23
HU227678B1 (en) 2011-11-28
CA2223449C (en) 2008-10-07
EA199700359A1 (ru) 1998-10-29
DE69637473D1 (de) 2008-05-08
AU704215B2 (en) 1999-04-15
HUP9900921A2 (hu) 1999-07-28
CA2223449A1 (en) 1996-12-19
NZ310778A (en) 1999-10-28
NO20041296L (no) 1998-02-05
MX9709315A (es) 1998-08-30
JP3059218B2 (ja) 2000-07-04
ATE390439T1 (de) 2008-04-15
AU6163496A (en) 1996-12-30
HK1015380A1 (en) 1999-10-15
DK0885242T3 (da) 2008-07-14
EP0885242A4 (en) 2000-03-22
CN1315870C (zh) 2007-05-16
EP0885242B1 (en) 2008-03-26
CZ389797A3 (cs) 1998-06-17
HUP9900921A3 (en) 1999-11-29
IL122102A0 (en) 1998-04-05
TW518341B (en) 2003-01-21
KR100436680B1 (ko) 2004-09-18
EA001220B1 (ru) 2000-12-25
CA2636432A1 (en) 1996-12-19
TR199701526T1 (xx) 1998-03-21
EP2338897A1 (en) 2011-06-29
AR003431A1 (es) 1998-08-05
PL188795B1 (pl) 2005-04-29
ES2303338T3 (es) 2008-08-01
PL323917A1 (en) 1998-04-27
EP2055712A1 (en) 2009-05-06
US6083913A (en) 2000-07-04
JPH10507776A (ja) 1998-07-28
EP1961760A2 (en) 2008-08-27
BR9608587A (pt) 1999-01-05
CN1966520A (zh) 2007-05-23
ZA964814B (en) 1998-02-09
US6465430B1 (en) 2002-10-15
NO975705L (no) 1998-02-05

Similar Documents

Publication Publication Date Title
PE7898A1 (es) Peptidos compuestos que se ligan al receptor de trombopoietina
ATE113063T1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
IE62744B1 (en) Lhrh antagonists, a process for preparing them and corresponding pharmaceutical preparations
NO965411L (no) N-terminalt forlengede proteiner uttrykt i gjær
SE9100799L (sv) Rekombinant derivat av human faktor viii
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
ATE162201T1 (de) Cnp-gen und vorläuferprotein aus schwein
TW224975B (es)
ES2058873T3 (es) Antagonistas peptidicos sinteticos de neuroquinina a, sus sales y procedimientos de preparacion respectivos.
NO975565L (no) Benstimulerende faktor
DE69120776D1 (de) Neue inhibitorische Peptide
NZ222076A (en) Analogs of gonadotropin-releasing factor and pharmaceutical compositions
HU9602223D0 (en) Biotin derivatives and pharmaceutical compositions containing them
DK0493581T3 (da) Rekombinant gen der koder for et protein med endochitinaseaktivitet
ES2063519T3 (es) Peptidos sinteticos que antagonizan neuroquinina a, sus sales y sus procedimientos de preparacion.
ES2069272T3 (es) Hexapeptidos con grupos esteres sulfato.
ATE425988T1 (de) Peptide mit affinitat fur ein phospholipid und deren verwendung
GEP19981435B (en) Peptides with Organo-Protective Activity, Pharmaceutical Composition and the Use Thereof
FR2787454B1 (fr) Inhibiteur de la topoisomerase ii
ES8605987A1 (es) Procedimiento para preparar polipeptidos inmunoterapeuticos
TH35998A (th) Lh-rh เป็ปไทด์ อะนาล็อก ประโยชน์ของสิ่งเหล่านั้นและองค์ประกอบทางเภสัชกรรมซึ่งประกอบด้วยสิ่งเหล่านั้น
IT1177963B (it) Agenti polipeptidici immunoterapeutici e procedimento di preparazione

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term